<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00660426</url>
  </required_header>
  <id_info>
    <org_study_id>04-1213</org_study_id>
    <nct_id>NCT00660426</nct_id>
  </id_info>
  <brief_title>Study Of Advanced Gastrointestinal Malignancies And Other Solid Tumors</brief_title>
  <official_title>Phase I Study Of Oxaliplatin, Gemcitabine And Capecitabine In Advanced Gastrointestinal Malignancies And Other Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dose escalation of oxaliplatin, gemcitabine and capecitabine in the treatment of patients
      with advanced gastrointestinal malignancies and other solid tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To define the maximum tolerated dose of oxaliplatin, gemcitabine and capecitabine in the
      treatment of patients with advanced gastrointestinal malignancies and other solid tumors.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2005</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">October 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To define the maximum tolerated dose of oxaliplatin, gemcitabine and capecitabine in the treatment of patients with advanced gastrointestinal malignancies and other solid tumors.</measure>
    <time_frame>At the end of dose escalation (approximately 18 months)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the dose-limiting toxicity of oxaliplatin, gemcitabine and capecitabine in the treatment of patients with advanced gastrointestinal malignancies and other solid tumors.</measure>
    <time_frame>Approximately 28 days into treatment</time_frame>
    <description>Completion of 1st cycle</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the incidence and severity of other toxicities of oxaliplatin, gemcitabine and capecitabine in the treatment of patients with advanced gastrointestinal malignancies and other solid tumors.</measure>
    <time_frame>30 days after the end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To perform a structured neurological assessment and questionnaire and report neurological toxicities of oxaliplatin when used with this combination.</measure>
    <time_frame>30 days after end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To perform correlative pharmacogenomic and pharmacokinetic tests for this novel regimen.</measure>
    <time_frame>Day 1, 7, 15, and 21</time_frame>
    <description>PKs - expanded cohort only</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Advanced Gastrointestinal Malignancies</condition>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>Dose Level 1 (starting level)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxaliplatin 85 mg/m2 IV on days 1 and 15.
Gemcitabine 800 mg/m2 IV on days 1 and 15.
Capecitabine 600 mg/m2 BID orally on days 1-7 and days 15-21 rounded off to the nearest 150 mg or 500 mg tablet.
Each cycle is 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxaliplatin 100 mg/m2 IV on days 1 and 15.
Gemcitabine 800 mg/m2 IV on days 1 and 15.
Capecitabine 600 mg/m2 BID orally on days 1-7 and days 15-21 rounded off to the nearest 150 mg or 500 mg tablet.
Each cycle is 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxaliplatin 100 mg/m2 IV on days 1 and 15.
Gemcitabine 800 mg/m2 IV on days 1 and 15.
Capecitabine 800 mg/m2 BID orally on days 1-7 and days 15-21 rounded off to the nearest 150 mg or 500 mg tablet.
Each cycle is 28 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxaliplatin 100 mg/m2 IV on days 1 and 15.
Gemcitabine 1000 mg/m2 IV on days 1 and 15.
Capecitabine 800 mg/m2 BID orally on days 1-7 and days 15-21 rounded off to the nearest 150 mg or 500 mg tablet.
Each cycle is 28 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <arm_group_label>Dose Level 1 (starting level)</arm_group_label>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_label>Dose Level 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <arm_group_label>Dose Level 1 (starting level)</arm_group_label>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_label>Dose Level 4</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <arm_group_label>Dose Level 1 (starting level)</arm_group_label>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_label>Dose Level 4</arm_group_label>
    <other_name>Xeloda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histological Diagnosis: Patients must have a histological or cytological proven
             advanced gastrointestinal or other solid malignancy.

          2. Measurable or Evaluable Disease: See RECIST Criteria: www.cancer.gov/dip/RECIST

          3. Age: Patients must be 18 years old or older. Because no dosing or toxicity data are
             currently available on the use of oxaliplatin in patients &lt;18 years of age, children
             are excluded from this study, but will be eligible for other pediatric Phase I
             single-agent trials, when available.

          4. Performance Status: NCI CTC 0-2.

          5. Life Expectancy: &gt;=8 weeks.

          6. Recovery from Prior Therapy: Patients must have recovered from the acute toxic effects
             of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study
             and must be without significant systemic illness (e.g. infection). No chemotherapy or
             radiotherapy may be given within 3 weeks prior to the start of protocol treatment.
             Patients must have received &lt;= 2 prior chemotherapy regimes.

          7. Recovery from Intercurrent Illness: Patients must have recovered from uncontrolled
             intercurrent illness including, but not limited to, ongoing or active infection,
             symptomatic congestive heart failure, unstable angina pectoris or cardiac arrhythmia.

          8. Hematological Status: Patients must have adequate bone marrow function which is
             defined as an absolute neutrophil count &gt;= 1,500/mm³, platelet count &gt;= 100,000/mm³
             and hemoglobin &gt;= 9 g/dl.

          9. Hepatic Function: Total bilirubin must be &lt;= institutional limit of normal (ULN).
             Transaminases (SGOT and/or SGPT) must be &lt;= 4 x ULN.

         10. Neurological Status: Patients must not have active CNS metastases. Patients with Grade
             2 or higher peripheral neuropathy are ineligible due to the potential neurological
             complications of oxaliplatin therapy.

         11. Renal Function: Patients must have adequate renal function defined as serum creatinine
             &lt;= 2.0 mg/dl or creatinine clearance &gt;= 60 ml/min/1.73m² for patients with creatinine
             levels above 2.0 mg/dl.

         12. Sexually Active Patients: For all sexually active patients, the use of adequate
             barrier contraception (hormonal or barrier method of birth control) will be required
             during therapy, prior to study entry and for the duration of study participation.
             Non-pregnant status will be determined in all women of childbearing potential.
             Pregnant and nursing women patients are not eligible.

         13. HIV-Positive Patients: Patients receiving anti-retroviral therapy (HAART) for HIV
             infection are excluded from the study because of possible pharmacokinetic
             interactions. Appropriate protocols will be offered to patients receiving HAART
             therapy, when indicated.

         14. No known hypersensitivity to oxaliplatin, gemcitabine or capecitabine

         15. No pre-existing clinically significant cardiac, hepatic or renal disease.

         16. Informed Consent: After being informed of the treatment involved, patients must give
             written consent. The patient should not have any serious medical or psychiatric
             illness that would prevent either the giving of informed consent or the receipt of
             treatment.

         17. Inclusion of Women and Minorities: Entry to this study is open to both men and women
             and to all racial and ethnic groups.

        Exclusion Criteria:
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benjamin Tan, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2008</study_first_submitted>
  <study_first_submitted_qc>April 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 17, 2008</study_first_posted>
  <last_update_submitted>April 22, 2013</last_update_submitted>
  <last_update_submitted_qc>April 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>cancer</keyword>
  <keyword>gastrointestinal</keyword>
  <keyword>tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

